CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

LY3832479Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug636 Control Wiki 0.38
drug2662 Vitamin C Wiki 0.30
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Immunogenicity of LY3832479 Given as a Single Intravenous Dose in Healthy Participants

The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation could last up to 16 weeks and may include up to 10 visits to the study center.

NCT04441931 Healthy Drug: LY3832479 Drug: Placebo

Primary Outcomes

Description: A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug

Time: Baseline through Follow-up (Week 12)

Secondary Outcomes

Description: PK: AUC of LY3832479

Measure: 2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3832479

Time: Day 1: Pre-dose through Day 85

Description: PK: Cmax of LY3832479

Measure: PK: Maximum Concentration (Cmax) of LY3832479

Time: Day 1: Pre-dose through Day 85

No related HPO nodes (Using clinical trials)